Background
Materials and Methods
Patients and data collection
Assessment of clinical, radiological and histological data
Statistical analysis
Results
Demographics and unadjusted survival
Whole cohort | Ex-smoker (ES) | Current smoker (CS) | Non-smoker (NS) | p-value (between ES and CS) | p-value (between ES and NS) | |
---|---|---|---|---|---|---|
N (%)a
| 132 (100%) | 66 (50.0) | 17 (12.8) | 45 (34.1) | ||
Pack years (SD) | 25.9 (17.66) | 23.1 (18.43) | 32.9 (13.65) | 0.006 | ||
Smoking years (SD) | 25.5 (13.54) | 21.8 (12.48) | 38.1 (8.48) | <0.001 | ||
Male N (%) | 97 (73.5) | 59 (90.8) | 14 (82.4) | 20 (44.4) | 0.312 | <0.001 |
Age at diagnosis (y)(SD) | 70.5 (9.80) | 72.4 (7.95) | 58.1 (9.93) | 71.7 (8.74) | <0.001 | 0.411 |
Age at death (y) (SD) | 74.4 (9.35) | 75.8 (8.06) | 63.1 (8.13) | 76.2 (8.47) | <0.001 | 0.877 |
Median survival (mo) | 45.0 | 36.0 | 52.0 | 55.0 | 0.029 | 0.034 |
Pulmonary function tests (mean (SD)) | ||||||
FVC% (SD)b
| 76.7 (18.51) | 75.6 (19.51) | 76.1 (17.48) | 78.3 (17.26) | 0.926 | 0.341 |
FEV1% (SD) | 77.0 (16.99) | 74.9 (17.64) | 75.1 (15.77) | 80.7 (16.26) | 0.866 | 0.050 |
FEV1/FVC% (SD) | 101.4 (9.68) | 100.0 (9.70) | 99.8 (11.84) | 103.7 (7.72) | 0.995 | 0.093 |
DLco% (SD)c
| 56.1 (17.51) | 53.8 (16.13) | 58.9 (19.49) | 58.2 (18.98) | 0.272 | 0.139 |
CPI (SD) | 39.9 (19.96) | 41.1 (13.63) | 37.9 (14.25) | 39.1 (14.67) | 0.312 | 0.341 |
Radiological diagnoses N (%) | ||||||
Definite UIP | 79 (61.7) | 37 (46.8) | 14 (61.7) | 28 (35.4) | 0.055 | 0.553 |
Possible UIP | 28 (21.9) | 19 (67.9) | 1 (3.6) | 8 (28.6) | 0.049 | 0.261 |
Not UIP | 21 (16.4) | 10 (47.6) | 2 (11.8) | 9 (42.9) | 0.723 | 0.794 |
Step-by-step multivariate analyses
HR | 95% CI |
p-value | |
---|---|---|---|
Univariate | |||
Ex-smoker | Reference | ||
Current smoker | 0.52 | 0.29 – 0.95 | 0.033 |
Model containing DLco% | |||
Ex-smoker | Reference | ||
Current smoker | 0.60 | 0.33 – 1.10 | 0.098 |
Dlco% | 0.97 | 0.96 – 0.99 | 0.001 |
Model containing CPI | |||
Ex-smoker | Reference | ||
Current smoker | 0.62 | 0.34 – 1.14 | 0.126 |
CPI | 1.03 | 1.01 – 1.05 | 0.001 |
Model containing DLco % and age | |||
Ex-smoker | Reference | ||
Current smoker | 1.32 | 062 – 2.72 | 0.472 |
Dlco% | 0.97 | 0.95 – 0.98 | <0.001 |
Age at diagnosis | 1.06 | 1.02 – 1.10 | 0.001 |
Model containing CPI and age | |||
Ex-smoker | Reference | ||
Current smoker | 1.63 | 0.75 – 3.54 | 0.217 |
CPI | 1.05 | 1.02 – 1.07 | < 0.001 |
Age at diagnosis | 1.07 | 1.03 – 1.12 | <0.001 |
Model containing DLco %, age and gender | |||
Ex-smoker | Reference | ||
Current smoker | 1.32 | 063 – 2.80 | 0.465 |
Dlco% | 0.97 | 0.95 – 0.99 | <0.001 |
Age at diagnosis | 1.06 | 1.03 – 1.10 | 0.001 |
Gender - female | Reference | ||
male | 1.10 | 0.45 – 2.69 | 0.831 |
Model containing CPI, age and gender | |||
Ex-smoker | Reference | ||
Current smoker | 1.66 | 0.76 – 3.64 | 0.203 |
CPI | 1.05 | 1.02 – 1.07 | <0.001 |
Age at diagnosis | 1.07 | 1.03 – 1.12 | <0.001 |
Gender - female | Reference | ||
male | 1.22 | 0.51 – 2.94 | 0.657 |
HR | 95% CI | p-value | |
---|---|---|---|
Univariate | |||
Ex-smoker | Reference | ||
Non-smoker | 0.64 | 0.42 – 0.97 | 0.037 |
Model containing DLco% | |||
Ex-smoker | Reference | ||
Non-smoker | 0.79 | 0.50 – 1.24 | 0.306 |
Dlco% | 0.97 | 0.95 – 0.98 | <0.001 |
Model containing CPI | |||
Ex-smoker | Reference | ||
Non-smoker | 0.75 | 0.48 – 1.17 | 0.197 |
CPI | 1.04 | 1.02 – 1.06 | <0.001 |
Model containing DLco % and age | |||
Ex-smoker | Reference | ||
Non-smoker | 0.82 | 0.52 – 1.27 | 0.371 |
Dlco% | 0.96 | 0.95 – 0.98 | <0.001 |
Age at diagnosis | 1.05 | 1.02 – 1.08 | 0.001 |
Model containing CPI and age | |||
Ex-smoker | Reference | ||
Non-smoker | 0.79 | 0.51 – 1.23 | 0.292 |
CPI | 1.05 | 1.03 – 1.07 | <0.001 |
Age at diagnosis | 1.06 | 1.03 – 1.09 | <0.001 |
Model containing DLco %, age and gender | |||
Ex-smoker | Reference | ||
Non-smoker | 1.32 | 0.76 – 2.30 | 0.324 |
Dlco% | 0.96 | 0.95 – 0.98 | <0.001 |
Age at diagnosis | 1.06 | 1.03 – 1.09 | <0.001 |
Gender - female | Reference | ||
male | 2.35 | 1.24 – 4.45 | 0.009 |
Model containing CPI, age and gender | |||
Ex-smoker | Reference | ||
Non-smoker | 1.22 | 0.71 – 2.10 | 0.472 |
CPI | 1.05 | 1.03 – 1.07 | <0.001 |
Age at diagnosis | 1.07 | 1.04 – 1.10 | <0.001 |
Gender - female | Reference | ||
male | 2.22 | 1.18 – 4.18 | 0.013 |
Comorbidities and medications
Non-smokers | Ex-smokers | Current smokers |
p-value | |
---|---|---|---|---|
Cardiovascular diseases a
| 34 (75.6) | 46 (69.7) | 12 (70.6) | 0.790 |
Coronary artery disease | 22 (48.9) | 29 (43.9) | 10 (58.8) | 0.537 |
Hypertension | 23 (51.1) | 28 (42.4) | 6 (35.3) | 0.474 |
Cerebral infarction | 3 (6.7) | 8 (12.1) | 2 (11.8) | 0.629 |
TIA | 3 (6.7) | 5 (7.6) | 0.511 | |
Diabetes | 13 (28.9) | 18 (27.3) | 1 (6.3) | 0.145 |
Heart failure b
| 16 (35.6) | 14 (21.2) | 3 (17.6) | 0.169 |
Asthma | 7 (15.6) | 9 (13.6) | 4 (23.5) | 0.605 |
Depression | 4 (8.9) | 4 (6.1) | 1 (6.3) | 0.832 |
GER | 3 (6.7) | 10 (15.2) | 1 (6.3) | 0.288 |
Lung cancer | 4 (6.1) | 5 (29.4) | <0.001 | |
COPD | 3 (4.5) | 7 (41.2) | <0.001 | |
OSA | 2 (4.4) | 3 (4.5) | 1 (6.3) | 0.969 |
Multivariate with DLco%a
| Multivariate with CPI a
| ||||
---|---|---|---|---|---|
N(%) | HR (95 % CI) | p-value | HR (95 % C I) | p-value | |
Cardiovascular diseases b
| 96 (72.7) | 1.6 (1.01 – 2.52) | 0.047 | 1.5 (0.94 – 2.38) | 0.086 |
Coronary artery disease | 65 (49.2) | 1.4 (0.92 – 2.05) | 0.124 | 1.4 (0.93 – 2.10) | 0.109 |
Hypertension | 60 (45.5) | 1.0 (0.69 – 1.52) | 0.900 | 1.0 (0.67 – 1.47) | 0.955 |
Heart failure c
| 36 (27.2) | 0.8 (053 – 1.25) | 0.339 | 0.8 (0.53 – 1.27) | 0.378 |
Cerebral infarction | 13 (9.8) | 0.8 (0.40 – 1.44) | 0.395 | 0.9 (0.45 – 1.63) | 0.638 |
TIA | 8 (6.1) | 1.1 (0.48 – 2.66) | 0.778 | 1.2 (0.52 – 2.89) | 0.648 |
Diabetes | 35 (26.5) | 1.3 (0.82 – 2.11) | 0.256 | 1.4 (1.03 – 1.07) | 0.198 |
OSA | 6 (4.5) | 0.5 (0.22 – 1.20) | 0.121 | 0.5 (0.21 – 1.59) | 0.105 |
GER | 14 (10.6) | 0.9 (0.49 – 1.74) | 0.799 | 0.9 (0.46 – 1.64) | 0.661 |
Asthma | 21 (15.9) | 1.6 (0.92 – 2.78) | 0.098 | 1.5 (0.89 – 2.66) | 0.126 |
COPD | 10 (7.6) | 2.5 (1.02 – 6.01) | 0.045 | 1.8 (0.78 – 4.27) | 0.163 |
Lung cancer | 9 (6.8) | 1.0 (0.48 – 2.15) | 0.965 | 0.9 (0.43 – 1.92) | 0.808 |
Depression | 10 (7.6) | 0.9 (0.43 – 2.06) | 0.880 | 0.8 (0.39 – 1.81) | 0.654 |
Medications | |||||
Statins | 56 (42.4) | 1.3 (0.85 – 2.06) | 0.215 | 1.4 (0.91 – 2.25) | 0.121 |
Beta-blockers | 57 (43.2) | 0.9 (0.58 – 1.35) | 0.566 | 0.9 (0.59 – 1.39) | 0.643 |
GER medication | 13 (9.8) | 0.9 (0.48 – 1.71) | 0.752 | 1.2 (0.64 – 2.28) | 0.556 |
ACE inhibitors or angiotensin 1 antagonists | 48 (36.4) | 1.4 (0.94 – 2.04) | 0.103 | 1.1 (0.70 – 1.66) | 0.737 |
Anticoagulants | 15 (11.4) | 1.1 (0.59 – 1.89) | 0.849 | 0.7 (0.39 – 1.37) | 0.332 |
Platelet function drugs d
| 58 (43.9) | 1.2 (0.77 – 1.88) | 0.420 | 1.3 (0.82 – 2.04) | 0.277 |
Inhaled corticosteroids | 12 (9.1) | 1.4 (0.71 – 2.83) | 0.327 | 1.0 (1.03 – 1.07) | 0.290 |
Antidiabetic drugs e
| 22 (16.7) | 1.6 (0.88 – 2.84) | 0.123 | 1.7 (0.94 – 3.03) | 0.082 |
Insulin | 9 (6.8) | 2.4 (0.95 – 6.24) | 0.063 | 2.8 (1.07 – 7.09) | 0.036 |
Thyroid medication | 16 (12.1) | 0.9 (0.49 – 1.81) | 0.858 | 1.0 (0.50 – 1.90) | 0.946 |
Allopurinol | 4 (3.0) | 0.8 (0.18 – 3.21) | 0.717 | 0.6 (0.14 – 2.37 ) | 0.439 |
Medication | N / % |
---|---|
No medication | 42 / 31.8 |
Total | |
Corticosteroids | 75 / 56.8 |
Azathioprine | 28 / 37.2 |
N-acetylcysteine | 30 / 40.0 |
Cyclophosphamide | 16 / 12.1 |
Pirfenidone | 6 / 4.5 |
Nintedanib | 3 / 2.3 |
Mycophenolate mofetil | 1 / 0.8 |
Single medication | |
Corticosteroids | 24 / 18.2 |
N-acetylcysteine | 11 / 8.3 |
Pirfenidone | 5 /3.8 |
Nintedanib | 1 /0.8 |
Triple therapy b
| 7 /5.3 |
Combined with prednisone as only medication | |
Azathioprine | 14 / 10.6 |
N-acetylcysteine | 13 / 9.8 |
Cyclophosphamide | 8 / 6.1 |
After prednisone therapy | |
Nintedanib | 2 /1.5 |
Before triple therapy | |
Cyclophosphamide + Corticosteroids | 2 / 1.5 |
After triple therapy | |
Pirfenidone | 1 / 0.8 |
Cyclophosphamide | 3 / 2.3 |
Mycophenolate | 1 / 0.8 |
Medication | N / % |
---|---|
Opioids a
| 27 / 20.5 |
Oxygen therapy | 45 /34.1 |
Ambulatory | 17 / 37.7 |
Long term | 28 / 21.1 |
Inhaled corticosteroids | 9 / 6.8 |
Short-acting beta-agonists | 7 / 5.3 |
Anticholinergic drugs | 2 / 1.5 |
Theophylline | 1 / 0.8 |
Montelukast | 1 / 0.8 |
Mycolytics | 3 / 2.3 |
Medication | N (%) |
---|---|
Statins | 56 (42.4) |
Beta-blockers | 57 (43.2) |
ACE inhibitors or angiotensin 1 antagonist | 48 (36.4) |
GER medication | 13 (9.8) |
Allopurinol | 4 (3.0) |
Anticoagulants | 15 (11.4) |
Antiplatelet therapy a
| 58 (43.9) |
Inhaled corticosteroids | 12 (9.1) |
Antidiabetic drugs b
| 22 (16.7) |
Insulin | 9 (6.8) |
Thyroid medication | 16 (12.1) |